Liposomal siRNA for Ovarian Cancer
Liposomal siRNA for Ovarian Cancer
复制标题
DOI：
10.1007/978-1-60327-295-7_3
复制
发表时间：
2009-01-01
期刊：
影响因子：
--
通讯作者：
Sood, Anil K.
中科院分区：
文献类型：
--
作者：
Mangala, Lingegowda S.;Han, Hee Dong;Sood, Anil K.
RNA干扰（RNA interference，RNAi）的发现是近十年来汽车领域最重要的发现之一。近年来，小干扰RNA（siRNA）介导的基因沉默作为一种新的治疗模式在临床前研究中开始显示出实质性的希望，因为它具有强大的基因选择性沉默。然而，直到最近，siRNA的体内递送是其用作治疗方式的主要障碍。我们已经使用中性脂质体，1，2-二油酰-sn-甘油-3-磷脂酰胆碱（DOPC），用于高效的体内siRNA递送。使用掺入DOPC脂质体中的Alexa-555标记的siRNA，我们已经证明了腹膜内或静脉内注射后的有效肿瘤内递送。此外，DOPC脂质体中的EphA 2靶向siRNA显示出显著的靶向调节和抗肿瘤功效。
Discovery of RNA interference (RNAi) has been one of the most important findings in the last ten),cars. In recent years, small interfering RNA (siRNA)-mediated gene silencing is beginning to show substantial promise as a new treatment modality in preclinical studies because of its robust gene selective silencing. However, Until recently, delivery of siRNA in vivo was a major impediment to its Use as a therapeutic modality. We have used a neutral liposome, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), for highly efficient in vivo siRNA delivery. Using siRNA tagged with Alexa-555, incorporated in DOPC liposomes, we have demonstrated efficient intra-tumoral delivery following either intraperitoneal or intravenous injection. Furthermore, EphA2-targeted siRNA in DOPC liposomes showed significant target modulation and anti-tumor efficacy.